Introduction
============

Globally, coronary heart disease is one of the most common, high-risk diseases and the major reason for death and disability. Acute myocardial ischemia/reperfusion injury (IRI) is the leading cause of coronary heart disease worldwide ([@b1-etm-0-0-9083]). After restoring blood supply to ischemic myocardium, dysfunction of cell metabolism and structural damage are further aggravated, which eventually lead to IRI ([@b2-etm-0-0-9083]). IRI is commonly seen after cardiac surgery. Oxidative stress is believed to be the major mechanism underlying the pathogenesis of IRI ([@b3-etm-0-0-9083],[@b4-etm-0-0-9083]). With the enhanced incidence of coronary heart diseases, myocardial infarction and cardiac surgery, IRI is a common focus of research. It is necessary to uncover the pathogenesis of IRI to effectively prevent its occurrence.

Long non-coding RNA (lncRNA) is a transcript with 200 nt in length and it cannot directly encode proteins ([@b5-etm-0-0-9083]). Several lncRNAs have been discovered to be dysregulated during the progression of IRI, which provides a promising direction for uncovering the pathogenesis of IRI ([@b6-etm-0-0-9083]). For example, it has previously been reported that lncRNA nuclear enriched abundant transcript 1 (NEAT1) can protect cardiomyocytes from apoptosis via targeting miR-520a by modulating expression levels of apoptosis-related proteins ([@b11-etm-0-0-9083]). Gong *et al* indicated that upregulation of MALAT1 exerts a critical role in promoting cardiomyocyte apoptosis by acting as a competing endogenous RNAs (ceRNA) to sponge miR-144([@b12-etm-0-0-9083]). In addition, knockdown of NEAT1 can protect against IRI by inhibiting troponin levels and cardiocytes apoptosis through regulation of the mitogen-activated protein kinase (MAPK) signaling pathway ([@b13-etm-0-0-9083]). Therefore, clarification of lncRNAs involved in the occurrence and development of IRI contributes to improve the prognosis of affected individuals.

lncRNA small nuclear host gene 16 (*SNHG16)* is an important member of the SNHG family, serving as an oncogene in osteosarcoma ([@b14-etm-0-0-9083]), bladder cancer ([@b15-etm-0-0-9083]), lung cancer ([@b16-etm-0-0-9083]), glioma ([@b17-etm-0-0-9083]), ovarian cancer ([@b18-etm-0-0-9083]) and breast cancer ([@b19-etm-0-0-9083]). Moreover, a previous study showed that *CTCFI-*induced upregulation of *SNHG16* accelerated cardiac hypertrophy by targeting the miR-182-5p/*IGF1* axis ([@b20-etm-0-0-9083]). Furthermore, *SNHG16* was found to promote proliferation and inflammatory response of macrophages through the miR-17-5p/*NF-*κB signaling pathway in patients with atherosclerosis ([@b21-etm-0-0-9083]). However, it is unclear whether *SNHG16* is involved in the proliferative change in cardiomyocytes following IRI. In the present study, we constructed both *in vivo* and *in vitro* IRI models by performing ligation of the anterior descending coronary artery (LAD) in mice and by exposing primary cardiomyocytes to H~2~O~2~, respectively. We aimed to discover the biological role of SNHG16 in affecting the proliferative ability of cardiomyocytes.

Materials and methods
=====================

### Establishment of I/R mouse model

A total of 50 male mice (180-220 g, 6-8 weeks of age) obtained from the Experimental Animal Center, Qingdao University were randomly divided into 5 groups (sham group and 4 time-point groups, 10 mice for each group). Mice were housed in a temperature controlled room (21±2˚C) with a 12:12-h light/dark cycle (lights on at 06:00). All mice had free access to water and food. Animal experiments were repeated in triplicate, and a total of 150 mice were used in this study. The mice were anesthetized with 10% chloral hydrate at a dose of 200-250 mg/kg, intubated, and mechanically ventilated. No mice exhibited signs of peritonitis after the administration of 10% chloral hydrate. After thoracotomy, the left anterior descending coronary artery was inserted using 4.0 suture at the beginning 2-3 cm. A small soft film was placed between the suture and the artery. Ligation was performed after observation of 15-min stabilization of breath and blood pressure. Thirty minutes later, the ligature was removed and reperfusion was allowed for 120 min. For the sham group, mice were subjected to thoracotomy without ligation. During the experiments, mouse electrocardiogram was monitored. ST segment elevation and upright T wave were observed after ligation, which were relieved after reperfusion. All animal protocols were approved by the Animal Ethics Committee of Qingdao University (Qingdao, Shandong, China).

### Cell culture

According to previously described methods ([@b22-etm-0-0-9083],[@b23-etm-0-0-9083]), newborn mice (1-2 days of age) were sacrificed by cervical dislocation (after being anesthetized using 10% chloral hydrate at a dose of 250 mg/kg). No mice exhibited signs of peritonitis after the administration of 10% chloral hydrate. Mouse heart was immediately collected, washed in ice-cold HBSS and cut into 1-mm^3^ pieces. Heart tissues were digested in trypsin containing 0.125% EDTA (ethylenediaminetetraacetic acid) overnight at 4˚C in the dark. On the following day, heart homogenate was incubated in collagenase II solution in a water bath shaker (37˚C, 100 x g). Dulbecco\'s modified Eagle\'s medium (DMEM) (Gibco; Thermo Fisher Scientific, Inc.) containing 10% fetal bovine serum (FBS) (Gibco; Thermo Fisher Scientific, Inc.) was utilized to maintain the activity of cardiomyocytes. In order to construct the IRI model *in vitro*, the cells were cultured in the medium containing 200 µmol/l H~2~O~2~ for 0, 6, 12, 24 h, respectively.

### Cell transfection

Cardiomyocytes were inoculated in a 96-well plate at 6x10^6^ cells/ml. Twenty-four hours later, the cells were transfected with plasmid using Lipofectamine 2000 (Invitrogen; Thermo Fisher Scientific, Inc.) following the manufacturer\'s instructions. After transfection for 24 h, the cells were then used for the experiments. The final concentration of the pRL-CMV plasmids was 0.1 µg/µl. All the mimics, inhibitors and plasmids were purchased from GenePharma (Shanghai, China). The sequences were: miR-770-5p mimic, 5\'-UCCAGUACCACGUGUCAGGGCCA-3\'; miRNA-770-5p-control, 5\'-UCGCUUGGUGCAGGUCGGGAA-3 and miR-770-5p inhibitor, 5\'-UGGCCCUGACACGUGGUACUGGA-3\'.

### RNA extraction and quantitative real-time polymerase chain reaction (qPCR)

Extraction of total RNA in cells was performed using TRIzol reagent (Invitrogen; Thermo Fisher Scientific, Inc.). RNA was reversely transcribed into complementary deoxyribose nucleic acid (cDNA), and the latter was applied for PCR using SYBR Green method (Takara) for 5 min at 94˚C, and 40 cycles for 30 sec at 94˚C, 30 sec at 55˚C and 90 sec at 72˚C with Roche LightCycler 480 (Roche, USA). U6 and GAPDH were enrolled as internal controls. Primers were as below: SNHG16 forward, 5\'-CAGAATGCCATGGTTTCCCC-3\' and reverse, 5\'-TGGCAAGAGACTTCCTGAGG-3\'; GAPDH forward, 5\'-CGGAGTCAACGGATTTGGTCGTAT-3\' and reverse, 5\'-AGCCTTCTCCATGGTGGTGAAGAC-3\'; U6 forward, 5\'-CTCGCTTCGGCAGCACA-3\' and reverse, 5\'-AACGCTTCACGAATTTGCGT-3\'.

### Dual-luciferase reporter gene assay

Cardiomyocytes were co-transfected with SNHG16-MT (mutant)/SNHG16-WT (wild-type) and miRNA-770-5p mimics/NC, respectively. After transfection of 48 h, cells were lysed for determining relative luciferase activity with a Promega device (Promega Corp.). The 3\'-UTR of wild-type EGFR and the containing mutations in the putative binding site were inserted downstream of the firefly luciferase reporter into the psiCHECK-2 vector (Promega Corp.). The corresponding mutant construct was created through mutating the seed regions of the miR-133b binding sites and was named as 3\'-UTR mut EGFR. Cells were seeded into a 12-well plate at 80% confluence and cotransfected with 0.5 µg reporter plasmid, 40 nM miR-133b mimics or negative control with Lipofectamine 2000. For the reason of transfection efficiency, all samples were cotransfected with 0.05 µg pRL-CMV plasmid expressing *Renilla* Luciferase (Promega Corp.) as an internal control. Luciferase assay was conducted 48 h after transfection by Dual Luciferase Reporter Assay System (Promega Corp.). Firefly luciferase activity was standardized to *Renilla* luciferase activity. There experiments were conducted three times for each assay.

### Cell Counting Kit-8 (CCK-8)

Cardiomyocytes were seeded in the 96-well plate at 2x10^3^ cells per well and cultured overnight. Absorbance (A) at 450 nm was recorded at the appointed time points using the CCK-8 Kit (Dojindo Laboratories) by the TECAN infinite M200 Multimode microplate reader (Tecan).

### 5-Ethynyl-2\'-deoxyuridine (EdU)

Cardiomyocytes were seeded in a 96-well plate with 300 cells per well. Cardiomyocytes were labeled with 50 µmol/l EdU at 37˚C for 2 h. After 30-min fixation in 4% paraformaldehyde, cells were incubated with phosphate-buffered saline (PBS) containing 0.5% Triton-100 for 20 min. After washing with PBS containing 3% bovine serum albumin (BSA), 100 µl of dying solution was applied per well for a 1-h incubation in dark. Subsequently, the cells were counterstained with 100 µl of Hoechst for 10 min. EdU-positive cells, Hoechst-labeled cells and merged images were captured under a fluorescent microscope (IX70; Olympus).

### Statistical analyses

Statistical Product and Service Solutions (SPSS) 18.0 (SPSS Inc.) was used for data analyses. Data are expressed as mean ± standard deviation. Differences between groups were analyzed by the t-test. Comparisons among multiple groups were performed by one-way analysis of variance (ANOVA) followed by least significant difference (LSD) analysis. Comparisons among four groups were analyzed by Tukey\'s test. Each experiment was repeated at least three times. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### SNHG16 is downregulated in IRI models

The *in vivo* IRI model in mice was first constructed by performing LAD. With the prolongation of reperfusion, the relative level of *SNHG16* was significantly downregulated ([Fig. 1A](#f1-etm-0-0-9083){ref-type="fig"}). Meanwhile, primary cardiomyocytes were isolated from newborn mice and subjected to H~2~O~2~ treatment. *SNHG16* was significantly downregulated as well with the prolongation of H~2~O~2~ treatment in cardiomyocytes ([Fig. 1B](#f1-etm-0-0-9083){ref-type="fig"}).

### SNHG16 accelerates the proliferation of cardiomyocytes

To uncover the biological function of *SNHG16* in IRI, we constructed pcDNA-SNHG16. Transfection of pcDNA-SNHG16 in untreated and H~2~O~2~-treated cardiomyocytes markedly upregulated the *SNHG16* level, indicating a high transfection efficacy ([Figs. 1C](#f1-etm-0-0-9083){ref-type="fig"} and [2A](#f2-etm-0-0-9083){ref-type="fig"}). At 48 and 72 h, transfection of pcDNA-SNHG16 in H~2~O~2~-treated cardiomyocytes enhanced the viability relative to the H~2~O~2~+pcDNA-NC group ([Fig. 2B](#f2-etm-0-0-9083){ref-type="fig"}). EdU assay identically showed an elevation in the EdU-positive rate after overexpression of SNHG16 in cardiomyocytes treated with H~2~O~2~ compared to H~2~O~2~+pcDNA-NC group ([Fig. 2C](#f2-etm-0-0-9083){ref-type="fig"}).

### SNHG16 was able to bind to miRNA-770-5p

In order to predict the targets of SNHG16, the sequence of *SNHG16* was obtained from NCBI (<https://www.ncbi.nlm.nih.gov>), and then the sequence was uploaded to the online tool miRDB (<http://mirdb.org>). The results showed that miRNA-30e-5p, miRNA-205-5p, miRNA-770-5p and miRNA-564 were predicted to be the targets of *SNHG16*. miRNA-770-5p was the only miRNA to be significantly upregulated after 24-h H~2~O~2~ treatment in the cardiomyocytes ([Fig. 3A](#f3-etm-0-0-9083){ref-type="fig"}). In mice undergoing 120-min I/R injury, only the miRNA-770-5p level was highly significantly upregulated ([Fig. 3B](#f3-etm-0-0-9083){ref-type="fig"}). Potential binding sequences between *SNHG16* and miRNA-770-5p were identified ([Fig. 3C](#f3-etm-0-0-9083){ref-type="fig"}). Transfection of the miR-770-5p-mimics and miR-770-5p-inhibitor significantly upregulated and downregulated miR-770-5p, respectively, in the cardiomyocytes when compared to the miR-770-5p-control ([Fig. 3D](#f3-etm-0-0-9083){ref-type="fig"}). Furthermore, luciferase activity was markedly reduced after co-transfection of SNHG16-WT and miRNA-770-5p mimics, verifying their binding relationship ([Fig. 3E](#f3-etm-0-0-9083){ref-type="fig"}). Transfection of the miRNA-770-5p inhibitor significantly upregulated the *SNHG16* level, and in contrast, transfection of the miRNA-770-5p mimics significantly elevated the *SNHG16* level ([Fig. 3F](#f3-etm-0-0-9083){ref-type="fig"}). Moreover, transfection of pcDNA-SNHG16 significantly downregulated the miRNA-770-5p level, confirming their negative correlation ([Fig. 3G](#f3-etm-0-0-9083){ref-type="fig"}).

### Overexpression of miRNA-770-5p reversed the role of SNHG16 in cardiomyocytes

Rescue experiments were carried out to explore the involvement of miRNA-770-5p in SNHG16-mediated cardiomyocyte cytoactivation. After H~2~O~2~ treatment, the upregulation of SNHG16 in cardiomyocytes transfected with pcDNA-SNHG16 was partially downregulated by co-transfection of miRNA-770-5p mimics ([Fig. 4A](#f4-etm-0-0-9083){ref-type="fig"}). Moreover, the enhanced EdU-positive rate in cardiomyocytes overexpressing SNHG16 was reduced to some extent by miRNA-770-5p overexpression ([Fig. 4B](#f4-etm-0-0-9083){ref-type="fig"}). Collectively, *SNHG16* promotes the cytoactivation of cardiomyocytes in H~2~O~2~-treated cardiomyocytes by negatively regulating miRNA-770-5p.

Discussion
==========

Ischemic heart disease following myocardial infarction and congestive heart failure is the leading cause of global death ([@b24-etm-0-0-9083]). With the improvement of therapeutic strategies, thrombolytic therapy is widely applied in the treatment of acute myocardial infarction. It is able to quickly restore the blood flow of the coronary artery in the ischemic area, causing myocardial reperfusion, and decline of necrotic myocardial area ([@b25-etm-0-0-9083]). However, studies have shown that reperfusion after ischemia can aggravate cardiomyocyte damage, mainly manifested by accelerated myocardial necrosis, myocardial infarct size expansion, no-reflow phenomenon, arrhythmia and other symptoms ([@b25-etm-0-0-9083],[@b26-etm-0-0-9083]). Therefore, how to minimize the occurrence of reperfusion injury has become the focus of research.

Recent studies have shown the involvement of lncRNAs in the regulation of cardiovascular disease ([@b27-etm-0-0-9083],[@b28-etm-0-0-9083]). Wang *et al* ([@b29-etm-0-0-9083]) reported that lncRNA NRF regulates programmed necrosis and myocardial injury during ischemia/reperfusion injury (IRI) by targeting miR-873, providing a potential target for the treatment of myocardial ischemic diseases. In focal myocardial IRI, lncRNA *UCA1* was found to negatively regulate p27 expression and to exert a pro-apoptotic role in primary cardiomyocytes ([@b30-etm-0-0-9083]). In the present paper, long non-coding RNA small nuclear host gene 16 (lncRNA SNHG16) was time-dependently downregulated in mice undergoing LAD and in primary cardiomyocytes treated with H~2~O~2~. Both CCK-8 and EdU assays demonstrated the promotive effect of *SNHG16* on the proliferative ability of cardiomyocytes. The findings indicate that SNHG16 may be a key regulator involved in IRI.

A growing body of evidence has confirmed that lncRNAs regulate miRNA expression and functions as competitive endogenous (ce)RNAs ([@b31-etm-0-0-9083],[@b32-etm-0-0-9083]). The ceRNA theory proposes a complex regulatory network involving miRNAs, lncRNAs and circular (circ)RNAs. They usually contain mRNA binding sites and influence tumor progression by competitively binding microRNA response elements (MREs) ([@b33-etm-0-0-9083]). For example, *SNHG16* was found to promote the proliferative ability of osteosarcoma by competitively binding miR-205 and further upregulating *ZEB1* ([@b14-etm-0-0-9083]). SNHG16 was found to mediate *HMGB1* expression by absorbing miR-218-5p, thus exerting a carcinogenic effect on pancreatic cancer ([@b36-etm-0-0-9083]). The present study found many miRNA-binding sites in the sequences of *SNHG16* through bioinformatics analysis. Furthermore, dual-luciferase reporter gene assay confirmed the binding between *SNHG16* and miRNA-770-5p. In primary cardiomyocytes, *SNHG16* was negatively correlated with miRNA-770-5p. In addition, overexpression of miRNA-770-5p partially reversed the role of *SNHG16* in accelerating cardiomyocyte proliferation.

In conclusion, *SNHG16* was downregulated in the IRI mouse model and in the H~2~O~2~-exposed primary cardiomyocytes. Overexpression of SNHG16 accelerated the proliferative ability of cardiomyocytes following IRI by negatively regulating miRNA-770-5p.
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![*SNHG16* is downregulated in the IRI models. (A) Relative level of *SNHG16* in mice undergoing sham operations for 60 min, and IRI for 0, 30, 60 and 120 min. ^\*^P\<0.05, ^\*\*^P\<0.01, ^\*\*\*^P\<0.001, compared to the sham group. (B) Relative level of *SNHG16* in primary cardiomyocytes exposed to H~2~O~2~ for 0, 6, 12 and 24 h. ^\*^P\<0.05, ^\*\*^P\<0.01, ^\*\*\*^P\<0.001, compared to the 0 h group. (C) Relative level of SNHG16 in primary cardiomyocytes transfected with pcDNA-NC and pcDNA-SNHG16. ^\*\*\*^P\<0.001, compared to the pcDNA-NC group. SNHG16, small nuclear host gene 16; IRI, ischemia/reperfusion injury.](etm-20-04-3221-g00){#f1-etm-0-0-9083}

![*SNHG16* accelerates the proliferative ability of cardiomyocytes. (A) Relative level of SNHG16 in the primary cardiomyocytes following transfection and/or exposure to H~2~O~2~ in the following groups, control+pcDNA-NC, H~2~O~2~+pcDNA-NC or H~2~O~2~+pcDNA-SNHG16. ^\#\#^P\<0.01, H~2~O~2~+pcDNA-SNHG16 group vs. H~2~O~2~+pcDNA-NC group, ^\*\*\*^P\<0.001, H~2~O~2~+pcDNA-SNHG16 vs. control+pcDNA-NC group. (B) CCK-8 assay demonstrates the viability in the primary cardiomyocytes in the groups: Control+pcDNA-NC, H~2~O~2~+pcDNA-NC or H~2~O~2~+pcDNA-SNHG16. ^\#^P\<0.05, ^\#\#^P\<0.01 H~2~O~2~+pcDNA-SNHG16 group vs. H~2~O~2~+pcDNA-NC group, ^\*^P\<0.05, ^\*\*^P\<0.01, H~2~O~2~+pcDNA-SNHG16 group vs. control+pcDNA-NC group. (C) DAPI-labeled, EdU-labeled and merged images of primary cardiomyocytes in the group: Control+pcDNA-NC, H~2~O~2~+pcDNA-NC or H~2~O~2~+pcDNA-SNHG16 (magnification, x100). SNHG16, small nuclear host gene 16.](etm-20-04-3221-g01){#f2-etm-0-0-9083}

![*SNHG16* binds to miR-770-5p. (A) Relative levels of miRNA-30e-5p, miRNA-205-5p, miRNA-770-5p and miRNA-564 in primary cardiomyocytes undergoing 0 or 24-h H~2~O~2~ exposure. ^\*\*\*^P\<0.001 H2O2-24 h group vs. H2O2-0 h group (B) Relative levels of miRNA-30e-5p, miRNA-205-5p, miRNA-770-5p and miRNA-564 in mice undergoing 60-min sham operation or 120-min IRI. ^\*^P\<0.05, ^\*\*\*^P\<0.001, I/R-120 min vs. sham 60 group (C) Potential binding sequences between *SNHG16* and miR-770-5p. (D) Relative level of miR-770-5p in primary cardiomyocytes transfected with miR-770-5p-control, miR-770-5p-mimics and miR-770-5p-inhibitor. ^\#\#\#^P\<0.001, miR-770-5p-inhibitor group vs. miR-770-5p-mimics group, ^\*\*\*^P\<0.001, miR-770-5p-inhibitor group vs. miR-770-5p-control group. (E) Dual-luciferase reporter gene assay showed the luciferase activity in cardiomyocytes co-transfected with SNHG16-MT/SNHG16-WT and miRNA-770-5p mimics/NC. ^\*\*^P\<0.01, miR-770-5p-mimics group vs. miR-770-5p-control group. (F) SNHG16 expression following miRNA-770-5p mimics or miRNA-770-5p inhibitor transfection. ^\#\#^P\<0.01, miR-770-5p-inhibitor group vs. miR-770-5p-mimics group, ^\*\*\*^P\<0.001, miR-770-5p-mimics group vs. miR-770-5p-control group. (G) Relative levels of miR-770-5p in cardiomyocytes transfected with pcDNA-NC or pcDNA-SNHG16. ^\*\*^P\<0.01, pcDNA-NC group vs. pcDNA-SNHG16 group. SNHG16, small nuclear host gene 16; IRI, ischemia/reperfusion injury.](etm-20-04-3221-g02){#f3-etm-0-0-9083}

![Overexpression of miR-770-5p reverses the effect of *SNHG16* on cardiomyocytes. (A) Relative level of SNHG16 in primary cardiomyocytes in the control+pcDNA-NC, H~2~O~2~+pcDNA-NC, H~2~O~2~+pcDNA-SNHG16 or H~2~O~2~+pcDNA-SNHG16+miR-770-5p mimic groups. ^\*^P\<0.05, ^\*\*\*^P\<0.001, compared to the control+pcDNA-NC group; ^&^P\<0.05, compared to the H~2~O~2~+pcDNA-SNHG16 group. (B) DAPI-labeled, EdU-labeled and merged images of primary cardiomyocytes transfected in the control+pcDNA-NC, H~2~O~2~+pcDNA-NC, H~2~O~2~+pcDNA-SNHG16 or H~2~O~2~+pcDNA-SNHG16+miR-770-5p mimic groups (magnification, x100). SNHG16, small nuclear host gene 16.](etm-20-04-3221-g03){#f4-etm-0-0-9083}
